Insight Molecular Diagnostics Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

IMDX$2.47-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2025	2024	2025	2024
Net revenue	$518	$104	$2,656	$280
Cost of revenues	168	32	974	141
Cost of revenues – amortization of acquired intangibles	—	22	7	44
Gross profit	350	50	1,675	95
Operating expenses:
Research and development	3,281	2,453	6,205	4,765
Sales and marketing	1,460	853	2,666	1,699
General and administrative	2,647	2,407	5,762	5,080
Change in fair value of contingent consideration	2,804	(1,031)	3,683	2,281
Impairment loss on held for sale assets	—	—	—	169
Total operating expenses	10,192	4,682	18,316	13,994
Loss from operations	(9,842)	(4,632)	(16,641)	(13,899)
Other (expenses) income:
Interest expense	(25)	(8)	(54)	(23)
Other income, net	125	110	282	263
Total other income, net	100	102	228	240
Loss before income taxes	(9,742)	(4,530)	(16,413)	(13,659)
Income taxes	—	—	—	—
Net loss	$(9,742)	$(4,530)	$(16,413)	$(13,659)
Net loss per share (Note 2):
Net loss attributable to common stockholders - basic and diluted	$(9,742)	$(4,587)	$(16,413)	$(13,922)
Net loss attributable to common stockholders per share - basic and diluted	$(0.30)	$(0.36)	$(0.57)	$(1.32)
Weighted average shares outstanding - basic and diluted	32,023	12,870	28,876	10,567

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.